المؤلفون: Gallo N., Quarta S., Massaro M., Carluccio M. A., Barca A., Cannoletta D., Siculella L., Salvatore L., Sannino A.

المساهمون: Gallo, N., Quarta, S., Massaro, M., Carluccio, M. A., Barca, A., Cannoletta, D., Siculella, L., Salvatore, L., Sannino, A.

مصطلحات موضوعية: angiogenesi, drug delivery system, L-lysine, microsphere, PLGA

الوصف: Vascularization is a highly conserved and considerably complex and precise process that is finely driven by endogenous regulatory processes at the tissue and systemic levels. However, it can reveal itself to be slow and inadequate for tissue repair and regeneration consequent to severe lesions/damages. Several biomaterial-based strategies were developed to support and enhance vasculogenesis by supplying pro-angiogenic agents. Several approaches were adopted to develop effective drug delivery systems for the controlled release of a huge variety of compounds. In this work, a microparticulate system was chosen to be loaded with the essential amino acid L-lysine, a molecule that has recently gained interest due to its involvement in pro-angiogenic, pro-regenerative, and anti-inflammatory mechanisms. Poly (lactic-co-glycolic acid), the most widely used FDA-approved biodegradable synthetic polymer for the development of drug delivery systems, was chosen due to its versatility and ability to promote neovascularization and wound healing. This study dealt with the development and the effectiveness evaluation of a PLGA-based microparticulate system for the controlled release of L-lysine. Therefore, in order to maximize L-lysine encapsulation efficiency and tune its release kinetics, the microparticle synthesis protocol was optimized by varying some processing parameters. All developed formulations were characterized from a morphological and physicochemical point of view. The optimized formulation was further characterized via the evaluation of its preliminary biological efficacy in vitro. The cellular and molecular studies revealed that the L-lysine-loaded PLGA microparticles were non-toxic, biocompatible, and supported cell proliferation and angiogenesis well by stimulating the expression of pro-angiogenic genes such as metalloproteinase-9, focal adhesion kinases, and different growth factors. Thus, this work showed the potential of delivering L-lysine encapsulated in PLGA microparticles as a cost-effective promoter ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000939977900001; volume:15; firstpage:479; journal:PHARMACEUTICS; https://hdl.handle.net/11587/488049Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85149134294; https://www.mdpi.com/1999-4923/15/2/479Test

الإتاحة: https://doi.org/10.3390/pharmaceutics15020479Test
https://hdl.handle.net/11587/488049Test
https://www.mdpi.com/1999-4923/15/2/479Test

المؤلفون: Mazzocchetti, L, Parollo, M, Sbragi, S, Barletta, V, Segreti, L, Di Cori, A, De Lucia, R, Grifoni, G, Soldati, E, Viani, S, Branchitta, G, Carluccio, M, Canu, A, Paperini, L, Zucchelli, G

المصدر: Europace ; volume 25, issue Supplement_1 ; ISSN 1099-5129 1532-2092

مصطلحات موضوعية: Physiology (medical), Cardiology and Cardiovascular Medicine

الوصف: Funding Acknowledgements Type of funding sources: None. Introduction A previously validated algorithm allows to accurately identify ventricular tachycardia (VT) exit site in a 17-segments American Heart Association left ventricle model in patients with structural heart disease (SHD). ADAS3D is a novel artificial-intelligence cardiac magnetic resonance (CMR) post-processing software which enables heterogeneous tissue channel (HTC) identification. Purpose The aim of this study is to compare inferred VT exit site between QRS-axis based model and HTC identification from CMR post-processing. Methods All subjects allocated to a CMR-guided or aided approach from a multicenter randomized clinical trial were analyzed. Patients with available 12-lead ECG of clinical VT obtained before ablation were analyzed in terms of concordance between VT site of origin inferred from a QRS-axis and location of HTCs in a 17-segments model. Results 10 out of 15 patients had 12-lead ECG of clinical VT (80% male, 60% with ischemic cardiomyopathy, mean age 63,5±16,95 years, mean tachycardia cycle length 373,7±99,55 ms). 7 out of 10 patients (70,00%) had at least one HTC located at VT exit site as predicted by a QRS axis-based algorithm. In all remaining cases (3 out of 10) HTC location was found in a segment adjacent to ECG-derived exit site. All patients underwent CMR-guided or CMR-aided VT ablation with acute clinical success (noninducibility of the clinical VT). Conclusion VT site of origin prediction via a QRS axis-based algorithm allows for reasonable prediction of HTC presence at inferred site of origin. Larger studies are needed in order to confirm such findings and their potential clinical implications.

الإتاحة: https://doi.org/10.1093/europace/euad122.297Test
https://academic.oup.com/europace/article-pdf/25/Supplement_1/euad122.297/50428358/euad122.297.pdfTest

المؤلفون: Bacigalupo I., Giaquinto F., Salvi E., Carnevale G., Vaccaro R., Matascioli F., Remoli G., Vanacore N., Lorenzini P., Arabia G., Amorosi A., Bargagli A. M., Bartorelli L., Basso C., Berardinelli M., Bernardi M. P., Bianchi C. B. N. A., Blandi L., Boschi F., Bruni A. C., Caci A., Caffarra P., Canevelli M., Capasso A., Cipollari S., Cozzari M., Di Costanzo A., Di Fiandra T., Di Palma A., Fabbo A., Francescone F., Gabelli C., Gainotti S., Galeotti F., Gambina G., Gasparini M., Giannini M. A., Gilli M., Giordano M., Greco A., Guaita A., Izzicupo F., Landoni F., Lidonnici E., Locuratolo N., Logroscino G., Lombardi A., Losito G., Lubian F., Lupinetti M. C., Madrigali S., Marra C., Masera F., Massaia M., Mastromattei A., Matera A., Matera M., Mazzoleni F., Melani C., Meloni S., Memeo E., Musso M., Notarelli A., Onofrj M., Palummeri E., Panetta V., Petrini C., Piccoli T., Pirani A., Piras S., Porro G., Possenti M., Rendina E., Riolo A., Riva L., Santini S., Scalmana S., Scarpelli N., Secreto P., Seganfreddo M., Sensi S., Severino C., Spadin P., Spallino P., Spinelli A. L., Stracciari A., Trabucchi M., Zaccardi A., Accardo E., Ahmad O., Ajena D., Alba G., Albanese A., Albergati A., Alessandria M., Alfieri P., Alimenti M., Aliprandi A., Altavilla R., Amaru S., Ambrosino I., Amideo F., Ammendola S., Amoruso F., Andreati C., Andreone V., Angeloni R., Annunziata F., Antenucci S., Appollonio I., Arcudi L., Ardillo M., Carmela M., Arena G., Arighi A., Arpino G., Bagala A., Baiano A., Balestrino A., Barbagallo M., Barbuto M., Bargnani C., Barone P., Bartoli A., Bauco C., Bellelli G., Bellini M. A., Bellora A., Benati G., Beretta S., Bergamini L., Bergonzini E., Bessi V., Bianchetti A., Bisio E., Boiardi R., Bollani E., Bologna L., Bolzetta F., Boni S., Borgogni T., Bottini G., Bottone I., Bove A., Bruno B. R., Bruno G., Bruno P., Bucca C., Buganza M., Buzzi G., Buzzi P., Cacchio' G., Cafarelli A., Cafazzo V., Caggiula M., Cagnin A., Calabrese G., Calabrese G. A., Calandra M., Caleri V., Calvani D., Camerlingo M., Cantello R., Capellari S., Capobianco G., Capoluongo M. C., Cappelletti R., Capra C., Caravona N., Stucchi C. M., Carluccio M. A., Carteri S., Casanova A., Caserta F., Caso P., Cassaniti G., Cassetta E., Casson S., Castiello V., Cattaruzza T., Ceccon A., Ceci M., Cella S., Cenciarelli S., Censori B., Cerqua G., Cerrone P., Cervera P., Chemotti S., Chiari A., Chiloiro R., Cirilli L., Clerici R., Coin A., Colacino G., Colacioppo F. P., Colao R., Colin A., Coluccia B., Conti G. M., Coppola F., Corbo M., Cossu A., Costa A., Costa G., Costa M., Cotelli M. S., Cottone S., Cozzolino M. I., Crucitti A., Cumbo E., Curra A., Dallocchio C., D'Amico F., D'Amore A., De Carolis S., De Donato M., De Feo P., De La Pierre F., De Laurentiis M., De Lauretis I., De Luca G. P., De Palma A., De Togni L., Demontis A., D'Epiro D., Desideri G., Desiderio M., Di Donato M., Di Emidio G., Di Giacopo R., Di Lazzaro V., Di Leo R., Di Marco S., Di Quarto G., Dijk B., Dikova N., Dioguardi M. S., Dominici F., Dotta M., Dotti C., Esposito D., Esposito S., Esposito Z., Ettorre E., Faccenda G., Falanga A., Falorni M., Falvo F., Fappani A., Farina E. I. M., Fascendini S., Fattapposta F., Favatella I., Femminella G. D., Ferrara S., Ferrari P., Ferraris A., Ferraro F., Ferri R., Ferrigno S., Francesco, Filippi M., Finelli A., Finelli C., Fiori M. R., Fiorillo F., Floris G., Fontanella A., Forgione L., Foti A., Foti F. F., Francesca N., Frediani F., Frontera G., Fulgido M. L., Fuschillo C., Gabbani L., Galati F., Galli R., Gallo A., Gallo L., Gallucci M., Galluccio G., Gareri P., Gasperi L., Gelmini G., Gennuso M., Gerace C., Ghersetti D., Giambattistelli F., Giantin V., Giordano B., Giorelli M., Giorgianni A., Giubilei F., Godi L., Gorelli L., Gragnaniello D., Granziera S., Greco G., Grella R., Grieco M., Grimaldi L., Guarino M., Guarnerio C., Guidi G., Guidi L., Iallonardo L., Iavarone A., Ingegni T., Insarda P., Ivaldi C., Labate C. R., Lacava R., Lalli F., Lammardo A. M., Laurienzo P. M., Leonardi A., Leotta M. R., Leuzzi R., Linarello S., Litterio P., Coco D. L., Storto M. R. L., Logi C., Logullo F. O., Lombardi F., Lorido A., Losavio F. A., Luca A., Lucio M. L., Ludovico L., Lunardelli M., Lupo M., Luzzi S., Maddestra M., Maio G., Maiotti M., Malagnino A. M., Mancini G., Manica A., Maniscalco M., Manni B., Manucra A., Manzoni L., Marabotto M., Marchesiello G., Marcon M., Marcone A., Marconi R., Margiotta A., Marianantoni A., Mariani D., Marino G., Marino S., Marinoni V., Marra A., Marrari M., Martelli M., Marti A., Martorana A., Marvardi M., Mascolo S., Alba Mastronuzzi V. M., Mazzi M. L., Mazzone A., Mecacci R., Mecocci P., Medici D., Mei D., Melandri G. G., Melis M., Meneghello F., Menon V., Menza C., Merlo P., Milan G., Milia A., Millia C. C., Minervini S., Mobilia C. A., Moleri M., Molteni E., Moniello G., Montanari S., Mormile M. T., Moro G., Moscato G., Mossello E., Mundo A. D., Mura G., Musca F., Musso A. M., Nardelli A., Nicosia V., Nociti V., Novelli A., Nuccetelli F., Orefice L., Orsucci D., Pace A., Paci C., Padoan R., Padovani A., Palleschi L., Palmisani M. T., Palmucci M., Palumbo P., Panico N. R., Pansini A., Pantieri R., Paolello P., Paolo S., Pardini M., Parnetti L., Parrotta E., Passamonte M., Pastore A., Pastorello E., Pelini L., Pellati M., Pellegrino M., Pelliccioni G., Pennisi M. G., Perini M., Perotta D., Persico D., Petrella V., Petri F., Piccininni M., Pierguidi L., Pierobon A., Pietrella A., Pilotto A., Pinto P., Pizza V., Plantone D., Plastino M., Poddighe P., Pomati S., Pompilio A., Pontecorvo M., Prelle A., Previdere G., Pucci E., Puoti G., Putzu V., Rabasca A., Raffaele M., Rainero I., Rais C., Rana M., Ranzenigo A., Rea G., Righetti E., Rinaldi G., Rini A., Rizzo M. R., Rizzo M., Rocca P., Roffredo L., Roglia D., Romagnoni F., Romano C., Romasco A., Romeo L., Ronzoni S., Rosci C. E., Rosso M., Rozzini R., Ruberto E., Ruberto S., Rungger G., Ruotolo G., Russo F., Russo G., Sabina R., Sacco S., Sacilotto G., Salemi G., Salotti P., Salvatore E., Sambati L., Sanges G., Santamaria F., Santilli I. M., Santoro M., Saponara R., Scarmagnan M., Scataglini F., Seccia L., Selmo V., Sicurella L., Silvestri A., Simone M., Sirca A., Sleiman I., Solla P., Spalletta G., Sperber S. A., Spinelli L., Spoegler F., Sucapane P., Suraci D., Tagliabue B., Tagliente S., Tamietti E., Tedeschi G., Tetto A., Tiezzi A., Tiraboschi P., Tognoni G., Tomasetti C., Torchia F., Toriello G., Trevisi G., Tripi G., Trombetta G., Tulliani A., Vaccina A. R., Valentinis L., Varricchio G., Vasquez G. A., Vella F., Verde F., Verlato C., Vezzadini G., Vidale S., Vignoli A., Villani D., Vitelli A., Volpentesta L., Volpi G., Vozza D., Wanderlingh P., Wenter C., Zaccherini D., Zanardo M., Zanette G., Zanetti M., Zanetti O., Zanferrari C., Zuffi M., Zupo V.

المساهمون: Bacigalupo, I., Giaquinto, F., Salvi, E., Carnevale, G., Vaccaro, R., Matascioli, F., Remoli, G., Vanacore, N., Lorenzini, P., Arabia, G., Amorosi, A., Bargagli, A. M., Bartorelli, L., Basso, C., Berardinelli, M., Bernardi, M. P., Bianchi, C. B. N. A., Blandi, L., Boschi, F., Bruni, A. C., Caci, A., Caffarra, P., Canevelli, M., Capasso, A., Cipollari, S., Cozzari, M., Di Costanzo, A., Di Fiandra, T., Di Palma, A., Fabbo, A., Francescone, F., Gabelli, C., Gainotti, S., Galeotti, F., Gambina, G., Gasparini, M., Giannini, M. A., Gilli, M., Giordano, M., Greco, A., Guaita, A., Izzicupo, F., Landoni, F., Lidonnici, E., Locuratolo, N., Logroscino, G., Lombardi, A., Losito, G., Lubian, F., Lupinetti, M. C., Madrigali, S., Marra, C., Masera, F., Massaia, M., Mastromattei, A., Matera, A., Matera, M., Mazzoleni, F., Melani, C., Meloni, S., Memeo, E., Musso, M., Notarelli, A., Onofrj, M., Palummeri, E., Panetta, V., Petrini, C., Piccoli, T., Pirani, A., Piras, S., Porro, G., Possenti, M., Rendina, E., Riolo, A., Riva, L., Santini, S., Scalmana, S., Scarpelli, N., Secreto, P., Seganfreddo, M., Sensi, S., Severino, C., Spadin, P., Spallino, P., Spinelli, A. L., Stracciari, A., Trabucchi, M., Zaccardi, A., Accardo, E., Ahmad, O., Ajena, D., Alba, G., Albanese, A., Albergati, A., Alessandria, M., Alfieri, P., Alimenti, M., Aliprandi, A., Altavilla, R., Amaru, S.

مصطلحات موضوعية: COVID-19, Centers for Cognitive Disorders and Dementia, Dementia, Memory clinic, National dementia plan, Public health, Survey

الوصف: Introduction: A new national survey has been carried out by the Italian Centers for Cognitive Disorders and Dementias (CCDDs). The aim of this new national survey is to provide a comprehensive description of the characteristics, organizational aspects of the CCDDs, and experiences during the COVID-19 pandemic. Methods: A list of all national CCDDs was requested from the delegates of each Italian region. The online questionnaire is divided in two main sections: a profile section, containing information on location and accessibility, and a data collection form covering organization, services, treatments, activities, and any service interruptions caused by the COVID-19 outbreak. Results: In total, 511 out of 534 (96%) facilities completed the profile section, while 450 out of 534 (84%) CCDDs also completed the data collection form. Almost half of the CCDDs (55.1%) operated for 3 or fewer days a week. About one-third of the facilities had at least two professional figures among neurologists, geriatricians and psychiatrists. In 2020, only a third of facilities were open all the time, but in 2021, two-thirds of the facilities were open. Conclusion: This paper provides an update on the current status of CCDDs in Italy, which still shows considerable heterogeneity. The survey revealed a modest improvement in the functioning of CCDDs, although substantial efforts are still required to ensure the diagnosis and care of patients with dementia.

العلاقة: volume:45; issue:2; firstpage:525; lastpage:538; numberofpages:14; journal:NEUROLOGICAL SCIENCES; https://hdl.handle.net/11388/324118Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85168267223

الإتاحة: https://doi.org/10.1007/s10072-023-06958-8Test
https://hdl.handle.net/11388/324118Test

المؤلفون: Camponeschi C., De Carluccio M., Amadio S., Clementi M. E., Sampaolese B., Volonte C., Tredicine M., Spica V. R., Di Liddo R., Ria F., Michetti F., Di Sante G.

المساهمون: Camponeschi, C., De Carluccio, M., Amadio, S., Clementi, M. E., Sampaolese, B., Volonte, C., Tredicine, M., Spica, V. R., Di Liddo, R., Ria, F., Michetti, F., Di Sante, G.

مصطلحات موضوعية: Arundic acid, Experimental autoimmune encephalomyeliti, Multiple sclerosi, S100B inhibitor, Animal, Caprylate, Disease Models, Encephalomyelitis, Autoimmune, Experimental, Female, Mice, Inbred C57BL, Molecular Targeted Therapy, S100 Calcium Binding Protein beta Subunit

الوصف: S100B is an astrocytic protein behaving at high concentration as a damage-associated molecular pattern molecule. A direct correlation between the increased amount of S100B and inflammatory processes has been demonstrated, and in particular, the inhibitor of S100B activity pentamidine has been shown to ameliorate clinical scores and neuropathologic-biomolecular parameters in the relapsing-remitting experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. This study investigates the effect of arundic acid (AA), a known inhibitor of astrocytic S100B synthesis, in the chronic experimental autoimmune encephalomyelitis, which is another mouse model of multiple sclerosis usually studied. By the daily evaluation of clinical scores and neuropathologic-molecular analysis performed in the spinal cord, we observed that the AA-treated group showed lower severity compared to the vehicle-treated mice, particularly in the early phase of disease onset. We also observed a significant reduction of astrocytosis, demyelination, immune infiltrates, proinflammatory cytokines expression and enzymatic oxidative reactivity in the AA-treated group. Overall, our results reinforce the involvement of S100B in the development of animal models of multiple sclerosis and propose AA targeting the S100B protein as a focused potential drug to be considered for multiple sclerosis treatment.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34948360; info:eu-repo/semantics/altIdentifier/wos/WOS:000738566100001; volume:22; issue:24; firstpage:13558; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; http://hdl.handle.net/11577/3418785Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85121316480

الإتاحة: https://doi.org/10.3390/ijms222413558Test
http://hdl.handle.net/11577/3418785Test

المؤلفون: Giuliani P., Carluccio M., Ciccarelli R.

المساهمون: Giuliani, P., Carluccio, M., Ciccarelli, R.

مصطلحات موضوعية: adenine-based compound, glioblastoma multiforme (GBM), purine metabolizing enzyme, purinergic receptor, purinome

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33613296; info:eu-repo/semantics/altIdentifier/wos/WOS:000619453700001; volume:12; issue:Article Number: 632622; firstpage:1; lastpage:6; numberofpages:6; journal:FRONTIERS IN PHARMACOLOGY; http://hdl.handle.net/11564/752833Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85101136893; https://www.frontiersin.org/articles/10.3389/fphar.2021.632622/fullTest

الإتاحة: https://doi.org/10.3389/fphar.2021.632622Test
http://hdl.handle.net/11564/752833Test

المؤلفون: Carluccio M. A., Martinelli R., Massaro M., Calabriso N., Scoditti E., Maffia M., Verri T., Gatta V., De Caterina R.

المساهمون: Carluccio, M. A., Martinelli, R., Massaro, M., Calabriso, N., Scoditti, E., Maffia, M., Verri, T., Gatta, V., De Caterina, R.

مصطلحات موضوعية: Endothelial cell, Endothelial dysfunction, Gene expression, Hydroxytyrosol, Microarray analysi, Nutrigenomic, Olive oil polyphenol, Transcriptomic, Down-Regulation, Gene Ontology, Human Umbilical Vein Endothelial Cell, Human, NF-kappa B, Phenylethyl Alcohol, Reproducibility of Result, Signal Transduction, Unfolded Protein Response, Up-Regulation, Gene Expression Profiling, Nutrigenomics

الوصف: Hydroxytyrosol (HT), a peculiar olive and olive oil phenolic antioxidant, plays a significant role in the endothelial and cardiovascular protection associated with olive oil consumption. However, studies examining the effects of HT on the whole-genome expression of endothelial cells, which are prominent targets for vasculo-protective effects of olive oil polyphenols, have been lacking. This study aims to comprehensively evaluate the genomic effects exerted by HT, at the transcriptional level, in endothelial cells under resting or proinflammatory conditions. Human umbilical vein endothelial cells (HUVECs) were treated with 10 μmol/L HT for 1 h and then stimulated with 5 ng/mL interleukin (IL)-1β for 3 h. Total RNA was extracted, and gene expression profile assessed with microarray analysis. Functional enrichment analysis and pathway analysis were performed by Ingenuity Pathways Analysis. Microarray data were validated by qRT-PCR. Fixing a significance threshold at 1.5-fold change, HT affected the expression of 708 and 599 genes, respectively, in HUVECs under resting and IL-1β-stimulated conditions; among these, 190 were common to both conditions. Unfolded protein response (UPR) and endoplasmic reticulum stress resulted from the two top canonical pathways common between HT and HT-IL-1β affected genes. IL-17F/A signaling was found in the top canonical pathways of HT modified genes under resting unstimulated conditions, whereas cardiac hypertrophy signaling was identified among the pathways affected by HT-IL-1β. The transcriptomic analysis allowed pinpointing immunological, inflammatory, proliferative, and metabolic-related pathways as the most affected by HT in endothelial cells. It also revealed previously unsuspected genes and related gene pathways affected by HT, thus broadening our knowledge of its biological properties. The unbiased identification of novel genes regulated by HT improves our understanding of mechanisms by which olive oil prevents or attenuates inflammatory diseases and identifies new genes to ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34836245; info:eu-repo/semantics/altIdentifier/wos/WOS:000725774300001; volume:13; issue:11; firstpage:1; lastpage:24; numberofpages:24; journal:NUTRIENTS; http://hdl.handle.net/11564/769690Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118684175; https://www.mdpi.com/2072-6643/13/11/3990Test

الإتاحة: https://doi.org/10.3390/nu13113990Test
http://hdl.handle.net/11564/769690Test
https://www.mdpi.com/2072-6643/13/11/3990Test

المؤلفون: Zuccarini M., Lambertucci C., Carluccio M., Giuliani P., Ronci M., Spinaci A., Volpini R., Ciccarelli R., Di Iorio P.

المساهمون: Zuccarini, M., Lambertucci, C., Carluccio, M., Giuliani, P., Ronci, M., Spinaci, A., Volpini, R., Ciccarelli, R., Di Iorio, P.

مصطلحات موضوعية: Adenosine A, receptor, Adipogenic differentiation, Adipogenic marker, Adipose stromal cells (ASCs), Subcutaneous adipose tissue, Adenosine A1 Receptor Agonist, Adult, Apoptosi, Biomarker, Cell Proliferation, Female, Human, Ligand, Mesenchymal Stem Cell, Necrosi, Obesity, Phosphatidylinositol 3-Kinase, Phosphorylation, Proto-Oncogene Proteins c-akt, Adenosine A1, Signal Transduction, Subcutaneous Fat, Adipogenesi, Body Weight

الوقت: 1

الوصف: Adenosine A1 receptor (A1R) activation, stimulating lipogenesis and decreasing insulin resistance, could be useful for metabolic syndrome management in obese subjects. Since full A1R agonists induce harmful side-effects, while partial agonists show a better pharmacological profile, we investigated the influence of two derivatives of the full A1R agonist 2-chloro-N6-cyclopentyladenosine (CCPA), C1 and C2 behaving as A1R partial agonists in animal models, on the adipogenic differentiation of stromal/stem cells (ASCs) from human subcutaneous adipose tissue, which mainly contribute to increase fat mass in obesity. The ASCs from normal-weight subjects showed increased proliferation and A1R expression but reduced adipogenic differentiation compared to obese individual-derived ASCs. Cell exposure to CCPA, C1, C2 or DPCPX, an A1R antagonist, did not affect ASC proliferation, while mainly C2 and DPCPX significantly decreased adipogenic differentiation of both ASC types, reducing the activity of glycerol-3-phosphate dehydrogenase and the expression of PPARγ and FABP-4, all adipogenic markers, and phosphorylation of Akt in the phosphatidylinositol-3-kinase pathway, which plays a key-role in adipogenesis. While requiring confirmation in in vivo models, our results suggest that A1R partial agonists or antagonists, by limiting ASC differentiation into adipocytes and, thereby, fat mass expansion, could favor development/worsening of metabolic syndrome in obese subjects without a dietary control.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34944069; info:eu-repo/semantics/altIdentifier/wos/WOS:000736248200001; volume:10; issue:12; firstpage:3560; journal:CELLS; http://hdl.handle.net/11564/773831Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85121294521; https://www.mdpi.com/2073-4409/10/12/3560Test

الإتاحة: https://doi.org/10.3390/cells10123560Test
http://hdl.handle.net/11564/773831Test
https://www.mdpi.com/2073-4409/10/12/3560Test

المؤلفون: Di Giuseppe F., Carluccio M., Zuccarini M., Giuliani P., Ricci-Vitiani L., Pallini R., De Sanctis P., Di Pietro R., Ciccarelli R., Angelucci S.

المساهمون: Di Giuseppe, F., Carluccio, M., Zuccarini, M., Giuliani, P., Ricci-Vitiani, L., Pallini, R., De Sanctis, P., Di Pietro, R., Ciccarelli, R., Angelucci, S.

مصطلحات موضوعية: Exosome, Glioblastoma (GBM), Glioblastoma-derived stem-like cells (GSCs), Microvesicle, Oncosome, Proteomic, Sequential centrifugal ultrafiltration (SCUF)

الوصف: Extracellular vesicles (EVs) released from tumor cells are actively investigated, since molecules therein contained and likely transferred to neighboring cells, supplying them with onco-genic information/functions, may represent cancer biomarkers and/or druggable targets. Here, we characterized by a proteomic point of view two EV subtypes isolated by sequential centrifugal ultrafiltration technique from culture medium of glioblastoma (GBM)-derived stem-like cells (GSCs) obtained from surgical specimens of human GBM, the most aggressive and lethal primary brain tumor. Electron microscopy and western blot analysis distinguished them into microvesicles (MVs) and exosomes (Exos). Two-dimensional electrophoresis followed by MALDI TOF analysis allowed us to identify, besides a common pool, sets of proteins specific for each EV subtypes with peculiar differences in their molecular/biological functions. Such a diversity was confirmed by identification of some top proteins selected in MVs and Exos. They were mainly chaperone or metabolic enzymes in MVs, whereas, in Exos, molecules are involved in cell–matrix adhesion, cell migra-tion/aggressiveness, and chemotherapy resistance. These proteins, identified by EVs from primary GSCs and not GBM cell lines, could be regarded as new possible prognostic markers/druggable targets of the human tumor, although data need to be confirmed in EVs isolated from a greater GSC number.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33546239; info:eu-repo/semantics/altIdentifier/wos/WOS:000622129100001; volume:9; issue:2 / Article Number: 146; firstpage:1; lastpage:23; numberofpages:23; journal:BIOMEDICINES; http://hdl.handle.net/11564/752838Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100745981; https://www.mdpi.com/2227-9059/9/2/146Test

الإتاحة: https://doi.org/10.3390/biomedicines9020146Test
http://hdl.handle.net/11564/752838Test
https://www.mdpi.com/2227-9059/9/2/146Test

المؤلفون: Palermo A., Ferrante F., Stanca E., Damiano F., GNONI, ANTONIO, Batani T., Carluccio M. A., Demitri C., Siculella L.

المساهمون: Palermo, A., Ferrante, F., Stanca, E., Damiano, F., Gnoni, Antonio, Batani, T., Carluccio, M. A., Demitri, C., Siculella, L.

مصطلحات موضوعية: Bilateral osseointegration, Dental implant, Growth factor

الوصف: This study aimed to evaluate the combined use of the Concentrated Growth Factor (CGF) and the liquid phase of CGF (LPCGF) on dental implant surfaces, using a medical device to determine the migration of growth factors, from the implant surface to the recipient. The implants were permeated by autologous growth factors, using a specific centrifuge device. CGF adhesion on the implant surface was evaluated through a scanning electron microscope analysis. To assess the release of the vascular endothelial growth factor (VEGF) from CGF, LPCGF, and CGF- or LPCGF-permeated implant, an ELISA assay was carried out. The results showed that the concentration of the growth factor VEGF was greater in CGF than in LPCGF. Our innovative technique allowed the incorporation of autologous growth factors on the surface of the dental implants. Moreover, we reported the release of VEGF, over time, by CGF- or LPCGF-permeated implant. On this basis, it was possible to obtain a biologically active implant surface, essential to create intercellular communication and neo-angiogenesis, to facilitate wound healing and tissue regeneration.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000473748100149; volume:9; issue:10; firstpage:2114; numberofpages:8; journal:APPLIED SCIENCES; http://hdl.handle.net/11586/236410Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85066482343; https://res.mdpi.com/applsci/applsci-09-02114/article_deploy/applsci-09-02114-v2.pdf?filename=&attachment=1Test

الإتاحة: https://doi.org/10.3390/app9102114Test
http://hdl.handle.net/11586/236410Test
https://res.mdpi.com/applsci/applsci-09-02114/article_deploy/applsci-09-02114-v2.pdf?filename=&attachment=1Test

المؤلفون: Di Cori, A, Viani, S, Tolve, S, Zucchelli, G, Barletta, V, Giannotti Santoro, M, Parollo, M, Cellamaro, T, Branchitta, G, Carluccio, M, Segreti, L, Paperini, L, De Lucia, R, Soldati, E, Bongiorni, M.G

المصدر: European Heart Journal ; volume 41, issue Supplement_2 ; ISSN 0195-668X 1522-9645

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الوصف: Background Subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless pacemakers (LPM) provide an alternative to transvenous implantable devices. Sometimes, after transvenous (TV) lead extraction, patients show a bilateral venous occlusion, resulting not eligible for TV reimplantation. Purpose This analysis was designed to provide preliminary data on feasibility and short-term outcome of an hybrid combination (Hyb) of s-ICD plus LPM after TV-ICD explantation, in patients without anatomical transvenous reimplantation options. Methods Among 2684 consecutive extracted patients, 31 (1.1%) were reimplanted with a LPM, 66 (2.4%) with a s-ICD and 6 (0.2%) patients with an Hyb combination. Hyb strategy was considered in patients with a pacing plus defibrillating indication, and an anatomical barrier, as bilateral superior venous occlusion or massive bilateral skin erosion. Results Hyb patients were old (72±10 years), with a prevalent ischemic disease (4/6) and a reduced ejection fraction (43±16%). Extraction indication was infection in 4 and severe venous occlusion in 2, and included 2 single chamber, 2 dual chamber and 2 biventricular ICD. After extraction, reimplantation timing was 7±6 days, LPM was implanted before and sICD the day after. LPM reimplantation indication was sinus node dysfunction in 2 and AV block in 4. Implantation duration was 68±23 and fluoroscopy time 9.4±2.3 min. ICD reimplantation indication was primary prevention in 4 and secondary prevention in 2. Implantation duration was 118±10 min. No complications were observed. At 1 year, no complications were observed, including device related cross-talks. Conclusions The Hyb strategy is a potential option after TV-ICD explantation in pacemaker dependent patients, when transvenous implantation is not available. Extraction and Reimplantation Session Funding Acknowledgement Type of funding source: None

الإتاحة: https://doi.org/10.1093/ehjci/ehaa946.0826Test
http://academic.oup.com/eurheartj/article-pdf/41/Supplement_2/ehaa946.0826/34514183/ehaa946.0826.pdfTest